AtmosR Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Crowdfunding

  • Latest Deal Amount
  • $967K

  • Investors
  • 4

AtmosR General Information

Description

Developer of neurological disorder therapeutics designed to address severe brain conditions through protein aggregation-targeted treatment. The company develops small molecule inhibitors, blood-brain barrier therapies, neuronal restoration compounds, and proteasome-triggered degradation technologies, enabling healthcare providers to reduce neuronal toxicity and support improved cellular function, neurological stability, and therapeutic accessibility.

Contact Information

Website
www.atmosr.com
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Corporate Office
  • Imp Des Lotiers
  • 13710 Fuveau
  • France
+33 06
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Imp Des Lotiers
  • 13710 Fuveau
  • France
+33 06

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AtmosR Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Equity Crowdfunding 30-Apr-2025 $967K Completed Generating Revenue
4. Accelerator/Incubator 10-Jun-2022 Completed Generating Revenue
3. Accelerator/Incubator 01-Jan-2022 Completed Generating Revenue
2. Accelerator/Incubator 01-Jan-2022 Completed Generating Revenue
1. Accelerator/Incubator 01-Jan-2022 Completed Generating Revenue
To view AtmosR’s complete valuation and funding history, request access »

AtmosR Patents

AtmosR Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024239653-A1 Adenine derivatives as hsp90 inhibitors Pending 17-Mar-2023
EP-4680606-A1 Adenine derivatives as hsp90 inhibitors Pending 17-Mar-2023
WO-2024194175-A1 Adenine derivatives as hsp90 inhibitors Inactive 17-Mar-2023
WO-2023006993-A1 Fused amino pyridine or pyrimidine derivatives for the treatment of congenital central hypoventilation syndrome Inactive 30-Jul-2021 A61K31/4745

AtmosR Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AtmosR Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
EIT Health Accelerator/Incubator
European Innovation Council Accelerator/Incubator
Incubateur Impulse Accelerator/Incubator
Neighborhood Accelerator/Incubator
To view AtmosR’s complete investors history, request access »

AtmosR FAQs

  • When was AtmosR founded?

    AtmosR was founded in 2019.

  • Where is AtmosR headquartered?

    AtmosR is headquartered in Fuveau, France.

  • What is the size of AtmosR?

    AtmosR has 9 total employees.

  • What industry is AtmosR in?

    AtmosR’s primary industry is Drug Discovery.

  • Is AtmosR a private or public company?

    AtmosR is a Private company.

  • What is the current valuation of AtmosR?

    The current valuation of AtmosR is .

  • What is AtmosR’s current revenue?

    The current revenue for AtmosR is .

  • How much funding has AtmosR raised over time?

    AtmosR has raised $1.04M.

  • Who are AtmosR’s investors?

    EIT Health, European Innovation Council, Incubateur Impulse, and Neighborhood have invested in AtmosR.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process